Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients

Prostate

Volumn 29, Issue 4, 1996, Pages 231-240

  Carraro, Jean Christophe ^a   Raynaud, Jean Pierre ^b   Koch, Gary ^o   Chisholm, Geoffrey D ^g   Di Silverio, Franco ⁱ   Teillac, Pierre ^d   Da Silva, Fernando Calais ^j   Cauquil, Joris ^a   Chopin, Dominique K ^e   Hamdy, Freddie C ^h   Hanus, Miroslav ^k   Hauri, Dieter ^l   Kalinteris, Athanasios ^m   Marencak, Josef ⁿ   Perier, Antoine ^c   Perrin, Paul ^f  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Analytica   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Antiquaille Hospital   (France)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF LISBON   (Portugal)

^k CHARLES UNIVERSITY   (Czech Republic)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁿ Skalica Hospital   (Slovakia)

^o UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

5 reductase inhibitor; benign prostatic hyperplasia; finasteride; lipid sterol extract of Serenoa repens; Permixon ; phytotherapy

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SABAL; SEXUAL FUNCTION; SYMPTOMATOLOGY; URINE FLOW RATE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OXIDOREDUCTASES; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA; SERENOA; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0347318854     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E     Document Type: Article

References (33)

1. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM: Natural history of prostatism: Relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153:1510-1515, 1995.
2. Barry MJ, Cockett ATK, Holtgrewe HL, McDonnell JD, Sihelnik SA, Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150:351-358, 1993.
3. Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, Bruskewitz RC: Controversies about indications for transurethral resection of the prostate. J Urol 141:475-481, 1989.
4. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG, for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332:75-79, 1995.
5. Barry MJ, Mulley AG Jr, Fowler FJ, Wennberg JW: Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA 259:3010-3017, 1988.
6. Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia: A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 150:1696-1700, 1993.
7. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McDonnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191, 1992.
8. Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ, Metcalf BW: Epristeride is a selective and specific uncompetitive inhibitor of steroid human 5α-reductase isoform 2. J Steroid Biochem Mol Biol 48:197-206, 1994.
9. Di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A: Endocrine properties of the testosterone 5α-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol 48:241-248, 1994.
10. Jardin A, Bensadoun H, Delauche-Cavallier, Attali P, the BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337:1457-1461, 1991.
11. Düker EM, Kopanski L, Schweikert HU: Inhibition of 5α-reductase activity by extracts from Sabal serrulata. Planta Med [Suppl] 5:Abst L2-2, 1989.
12. Buck AC, Cox R, Rees RWM, Ebeling L, John A: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. Br J Urol 66:398-404, 1990.
13. Fitzpatrick JM, Dreikorn K, Habib F, Mebust WK, Perrin P, Schulze HK: Medical management of benign prostatic hyperplasia other than with hormones of alpha blockers. Prog Clin Biol Res 386:303-309, 1994.
14. Champault G, Patel JC, Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18:461-462, 1984.
15. Berges RR, Windeler, J, Trampisch HJ, Serge T, β-Sitosterol Study Group: Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 545:1529-1532, 1995.
16. Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P: Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol 20:68-77, 1991.
17. Habib FK, Chisholm GD: The role of growth factors in the human prostate. Scand J Urol Nephrol [Suppl] 138: 53-58, 1991.
18. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, McLoughlin MG: Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab 67:806-816, 1988.
19. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD: Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 595:53-66, 1990.
20. Ragab A, Ragab-Thomas JMF, Delhon A, Tisne-Versailles J, Gassama-Diagne A, Fauvel J, Cousinier JP, Chap H, Douste-Blazy L: Effects of Permixon® (Sereprostat® in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. In: "New Trends in Bladder Cancer Chemotherapy. New Trends in BPH Etiopathogenesis." Acta Medica, 1987, pp. 293-296.
21. Délos S, Iehlé C, Martin PM, Raynaud JP: Inhibition of the activity of "basic" 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48: 347-352, 1994.
22. Tayrayre JP, Delhon A, Lauressergues H, Stenger A: Action anti-oedémateuse d'un extrait hexanique de drupes de Serenoa repens Batr. Ann Pharm Fr 41:559-570, 1983.
23. Di Silverio F, d'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M, Sciarra F: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 21:309-314, 1992.
24. Drach GW, Layton TN, Binard WJ: Male peak urinary flow rate: Relationships to voided volume and age. J Urol 122:210-214, 1979.
25. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549-1557, 1992.
26. Birch NC, Hurst G, Doyle PT: Serial residual volumes in men with prostatic hypertrophy. Br J Urol 62:571, 1988.
27. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74:505-508, 1992.
28. Geller J: Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 71:1552-1555, 1990.
29. Guess HA, Heyse JF, Gormley GJ: The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 22:31-37, 1993.
30. Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299, 1993.
31. Mantzoros CS, Georgiadis EI, Trichopoulos D: Contribution of dihydrotestosterone to male sexual behaviour. Br Med J [Clin Res] 310:1289-1290, 1995.
32. Rhodes L, Primka R, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B: Comparison of finasteride, a 5α-reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α-reductase inhibition. Prostate 22:43-51, 1993.
33. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 186:1213-1215, 1974.